-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec On November 22, 2021, BeiGene announced that the first patient who has completed Phase 1 clinical trials of the potent tyrosine kinase 2 (TYK2) inhibitor BGB-23339 under investigation has been given to Medicine
.
As a highly selective allosteric TYK2 inhibitor, BGB-23339 has shown effective inhibition of pro-inflammatory cytokines in preclinical studies, and is expected to be used in the treatment of diseases such as psoriasis and inflammatory bowel disease
.
The press release states that this is BeiGene's first internally developed candidate therapy for inflammation and immune diseases
.
TYK2 is a member of the Janus kinase (JAK) family of proteins.
It is an intracellular signal kinase that mediates interleukin (IL)-23, IL-12 and type I interferon signal transduction
.
It plays an important role in transmitting inflammation and immune response signals, and is considered to be related to the pathology of a variety of immune-mediated diseases
.
BGB-23339 is a highly selective allosteric TYK2 inhibitor
.
It is designed to target the regulatory pseudokinase (JH2) domain on TYK2.
It has shown strong selectivity in preclinical studies and can effectively inhibit IL-12, IL-23 and type I IFN and other pro-inflammatory cytokines
.
Its phase 1 clinical trial aims to evaluate the safety, tolerability, pharmacokinetics and preliminary activity of BGB-23339, and it is expected that 115 healthy volunteers will be enrolled
.
"BGB-23339, discovered and developed by BeiGene, is a highly selective and potent allosteric TYK2 inhibitor and has shown good activity in preclinical evaluation
.
"Dr.
Wang Lai, Head of Global R&D at BeiGene, commented, "Based on our positive results in oncology, BeiGene is expanding its clinical focus to discover new areas of high unmet needs such as inflammation and immunology.
Models and treatment platforms bring innovative and influential drugs to patients
.
"Reference: [1] BeiGene Initiates First-in-Human Phase1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339.
Retrieved November 22, 2021, from https:// Statement: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only.
The views
in the
article do not represent WuXi AppTec's position, nor do they support or oppose WuXi AppTec's views in the article .
This article is not a treatment plan.
Recommended
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
.
As a highly selective allosteric TYK2 inhibitor, BGB-23339 has shown effective inhibition of pro-inflammatory cytokines in preclinical studies, and is expected to be used in the treatment of diseases such as psoriasis and inflammatory bowel disease
.
The press release states that this is BeiGene's first internally developed candidate therapy for inflammation and immune diseases
.
TYK2 is a member of the Janus kinase (JAK) family of proteins.
It is an intracellular signal kinase that mediates interleukin (IL)-23, IL-12 and type I interferon signal transduction
.
It plays an important role in transmitting inflammation and immune response signals, and is considered to be related to the pathology of a variety of immune-mediated diseases
.
BGB-23339 is a highly selective allosteric TYK2 inhibitor
.
It is designed to target the regulatory pseudokinase (JH2) domain on TYK2.
It has shown strong selectivity in preclinical studies and can effectively inhibit IL-12, IL-23 and type I IFN and other pro-inflammatory cytokines
.
Its phase 1 clinical trial aims to evaluate the safety, tolerability, pharmacokinetics and preliminary activity of BGB-23339, and it is expected that 115 healthy volunteers will be enrolled
.
"BGB-23339, discovered and developed by BeiGene, is a highly selective and potent allosteric TYK2 inhibitor and has shown good activity in preclinical evaluation
.
"Dr.
Wang Lai, Head of Global R&D at BeiGene, commented, "Based on our positive results in oncology, BeiGene is expanding its clinical focus to discover new areas of high unmet needs such as inflammation and immunology.
Models and treatment platforms bring innovative and influential drugs to patients
.
"Reference: [1] BeiGene Initiates First-in-Human Phase1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339.
Retrieved November 22, 2021, from https:// Statement: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only.
The views
in the
article do not represent WuXi AppTec's position, nor do they support or oppose WuXi AppTec's views in the article .
This article is not a treatment plan.
Recommended
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
